France’s Framatome and IBA (Ion Beam Applications, Euronext), a specialist in particle accelerator technology and ...

Astatine-211 (At-211) is one of a handful of promising alpha emitting radioisotopes for cancer therapy. Its short 7.2-hour half-life means that it must be handled quickly to minimize losses due to ...

Researchers in Japan are developing world-leading expertise in making and using the alpha particle emitter, astatine-211 (211 At), which has potential for use as a strong radionuclide therapy for ...

The secure, scalable, and timely supply of Astatine-211 is vital for addressing unmet medical needs, and we are committed to building a robust production network to serve the growing demand.

Astatine-211 is an alpha-emitting radioisotope used in cancer-fighting medical applications called targeted alpha therapy (TAT). The radioisotope has a 7.2-hour half-life, requiring new approaches ...

and GOTHENBURG, Sweden, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, and Atley Solutions, a global leader in commercial products and ...